This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guirakhoo, F.
Right arrow Articles by Monath, T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guirakhoo, F.
Right arrow Articles by Monath, T. P.

 Previous Article  |  Next Article 

Journal of Virology, June 2000, p. 5477-5485, Vol. 74, No. 12
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates

F. Guirakhoo,1,* R. Weltzin,1 T. J. Chambers,2 Z.-X. Zhang,1 K. Soike,3 M. Ratterree,3 J. Arroyo,1 K. Georgakopoulos,1 J. Catalan,1 and T. P. Monath1

OraVax, Inc., Cambridge, Massachusetts 021391; Department of Molecular Microbiology and Immunology, St. Louis University Medical School, St. Louis, Missouri 631042; and Tulane Regional Primate Research Center, Covington, Louisiana 704333

Received 24 January 2000/Accepted 20 March 2000

A chimeric yellow fever (YF)-dengue type 2 (dengue-2) virus (ChimeriVax-D2) was constructed using a recombinant cDNA infectious clone of a YF vaccine strain (YF 17D) as a backbone into which we inserted the premembrane (prM) and envelope (E) genes of dengue-2 virus (strain PUO-218 from a case of dengue fever in Bangkok, Thailand). The chimeric virus was recovered from the supernatant of Vero cells transfected with RNA transcripts and amplified once in these cells to yield a titer of 6.3 log10 PFU/ml. The ChimeriVax-D2 was not neurovirulent for 4-week-old outbred mice inoculated intracerebrally. This virus was evaluated in rhesus monkeys for its safety (induction of viremia) and protective efficacy (induction of anti-dengue-2 neutralizing antibodies and protection against challenge). In one experiment, groups of non-YF-immune monkeys received graded doses of ChimeriVax-D2; a control group received only the vaccine diluents. All monkeys (except the control group) developed a brief viremia and showed no signs of illness. Sixty-two days postimmunization, animals were challenged with 5.0 log10 focus forming units (FFU) of a wild-type dengue-2 virus. No viremia (<1.7 log10 FFU/ml) was detected in any vaccinated group, whereas all animals in the placebo control group developed viremia. All vaccinated monkeys developed neutralizing antibodies in a dose-dependent response. In another experiment, viremia and production of neutralizing antibodies were determined in YF-immune monkeys that received either ChimeriVax-D2 or a wild-type dengue-2 virus. Low viremia was detected in ChimeriVax-D2-inoculated monkeys, whereas all dengue-2-immunized animals became viremic. All of these animals were protected against challenge with a wild-type dengue-2 virus, whereas all YF-immune monkeys and nonimmune controls became viremic upon challenge. Genetic stability of ChimeriVax-D2 was assessed by continuous in vitro passage in VeroPM cells. The titer of ChimeriVax-D2, the attenuated phenotype for 4-week-old mice, and the sequence of the inserted prME genes were unchanged after 18 passages in Vero cells. The high replication efficiency, attenuation phenotype in mice and monkeys, immunogenicity and protective efficacy, and genomic stability of ChimeriVax-D2 justify it as a novel vaccine candidate to be evaluated in humans.

* Corresponding author. Mailing address: OraVex, Inc., 38 Sidney St., Cambridge, MA 02139. Phone: (617) 494-1339. Fax: (617) 494-0927. E-mail: fguirakhoo{at}oravax.com.

Journal of Virology, June 2000, p. 5477-5485, Vol. 74, No. 12
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Johnson, B. W., Kosoy, O., Hunsperger, E., Beltran, M., Delorey, M., Guirakhoo, F., Monath, T. (2009). Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests. CVI 16: 1052-1059 [Abstract] [Full Text]  
  • Yoshii, K., Goto, A., Kawakami, K., Kariwa, H., Takashima, I. (2008). Construction and application of chimeric virus-like particles of tick-borne encephalitis virus and mosquito-borne Japanese encephalitis virus. J. Gen. Virol. 89: 200-211 [Abstract] [Full Text]  
  • RAJA, N. U., HOLMAN, D. H., WANG, D., RAVIPRAKASH, K., JUOMPAN, L. Y., DEITZ, S. B., LUO, M., ZHANG, J., PORTER, K. R., DONG, J. Y. (2007). INDUCTION OF BIVALENT IMMUNE RESPONSES BY EXPRESSION OF DENGUE VIRUS TYPE 1 AND TYPE 2 ANTIGENS FROM A SINGLE COMPLEX ADENOVIRAL VECTOR. Am J Trop Med Hyg 76: 743-751 [Abstract] [Full Text]  
  • Holman, D. H., Wang, D., Raviprakash, K., Raja, N. U., Luo, M., Zhang, J., Porter, K. R., Dong, J. Y. (2007). Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes. CVI 14: 182-189 [Abstract] [Full Text]  
  • Chambers, T. J., Jiang, X., Droll, D. A., Liang, Y., Wold, W. S. M., Nickells, J. (2006). Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice.. J. Gen. Virol. 87: 3131-3140 [Abstract] [Full Text]  
  • HIGGS, S., VANLANDINGHAM, D. L., KLINGLER, K. A., MCELROY, K. L., MCGEE, C. E., HARRINGTON, L., LANG, J., MONATH, T. P., GUIRAKHOO, F. (2006). GROWTH CHARACTERISTICS OF CHIMERIVAX-DEN VACCINE VIRUSES IN AEDES AEGYPTI AND AEDES ALBOPICTUS FROM THAILAND. Am J Trop Med Hyg 75: 986-993 [Abstract] [Full Text]  
  • Calvert, A. E., Huang, C. Y.-H., Kinney, R. M., Roehrig, J. T. (2006). Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 87: 339-346 [Abstract] [Full Text]  
  • BRANDLER, S., BROWN, N., ERMAK, T. H., MITCHELL, F., PARSONS, M., ZHANG, Z., LANG, J., MONATH, T. P., GUIRAKHOO, F. (2005). REPLICATION OF CHIMERIC YELLOW FEVER VIRUS-DENGUE SEROTYPE 1-4 VIRUS VACCINE STRAINS IN DENDRITIC AND HEPATIC CELLS. Am J Trop Med Hyg 72: 74-81 [Abstract] [Full Text]  
  • Guirakhoo, F., Zhang, Z., Myers, G., Johnson, B. W., Pugachev, K., Nichols, R., Brown, N., Levenbook, I., Draper, K., Cyrek, S., Lang, J., Fournier, C., Barrere, B., Delagrave, S., Monath, T. P. (2004). A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys. J. Virol. 78: 9998-10008 [Abstract] [Full Text]  
  • Mathenge, E. G. M., Parquet, M. d. C., Funakoshi, Y., Houhara, S., Wong, P. F., Ichinose, A., Hasebe, F., Inoue, S., Morita, K. (2004). Fusion PCR generated Japanese encephalitis virus/dengue 4 virus chimera exhibits lack of neuroinvasiveness, attenuated neurovirulence, and a dual-flavi immune response in mice. J. Gen. Virol. 85: 2503-2513 [Abstract] [Full Text]  
  • Charlier, N., Molenkamp, R., Leyssen, P., Paeshuyse, J., Drosten, C., Panning, M., De Clercq, E., Bredenbeek, P. J., Neyts, J. (2004). Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice. J. Virol. 78: 7418-7426 [Abstract] [Full Text]  
  • Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., Lang, J., Ocran, S., Mitchell, F., Parsons, M., Brown, N., Brandler, S., Fournier, C., Barrere, B., Rizvi, F., Travassos, A., Nichols, R., Trent, D., Monath, T. (2004). Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates. J. Virol. 78: 4761-4775 [Abstract] [Full Text]  
  • Harvey, T. J., Liu, W. J., Wang, X. J., Linedale, R., Jacobs, M., Davidson, A., Le, T. T. T., Anraku, I., Suhrbier, A., Shi, P.-Y., Khromykh, A. A. (2004). Tetracycline-Inducible Packaging Cell Line for Production of Flavivirus Replicon Particles. J. Virol. 78: 531-538 [Abstract] [Full Text]  
  • JOHNSON, B. W., CHAMBERS, T. V., CRABTREE, M. B., GUIRAKHOO, F., MONATH, T. P., MILLER, B. R. (2004). ANALYSIS OF THE REPLICATION KINETICS OF THE CHIMERIVAXTM-DEN 1, 2, 3, 4 TETRAVALENT VIRUS MIXTURE IN AEDES AEGYPTI BY REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION. Am J Trop Med Hyg 70: 89-97 [Abstract] [Full Text]  
  • Chambers, T. J., Liang, Y., Droll, D. A., Schlesinger, J. J., Davidson, A. D., Wright, P. J., Jiang, X. (2003). Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model. J. Virol. 77: 3655-3668 [Abstract] [Full Text]  
  • Markoff, L., Pang, X., Houng, H.-s., Falgout, B., Olsen, R., Jones, E., Polo, S. (2002). Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys. J. Virol. 76: 3318-3328 [Abstract] [Full Text]  
  • Pletnev, A. G., Putnak, R., Speicher, J., Wagar, E. J., Vaughn, D. W. (2002). From the Cover: West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. USA 99: 3036-3041 [Abstract] [Full Text]  
  • Blaney, J. E. Jr., Johnson, D. H., Firestone, C.-Y., Hanson, C. T., Murphy, B. R., Whitehead, S. S. (2001). Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice. J. Virol. 75: 9731-9740 [Abstract] [Full Text]  
  • Pletnev, A. G., Bray, M., Hanley, K. A., Speicher, J., Elkins, R. (2001). Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes. J. Virol. 75: 8259-8267 [Abstract] [Full Text]  
  • Guirakhoo, F., Arroyo, J., Pugachev, K. V., Miller, C., Zhang, Z.-X., Weltzin, R., Georgakopoulos, K., Catalan, J., Ocran, S., Soike, K., Ratterree, M., Monath, T. P. (2001). Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. J. Virol. 75: 7290-7304 [Abstract] [Full Text]  
  • Hurrelbrink, R. J., McMinn, P. C. (2001). Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein. J. Virol. 75: 7692-7702 [Abstract] [Full Text]  
  • Vaughn, D. W. (2000). Invited Commentary: Dengue Lessons from Cuba. Am J Epidemiol 152: 800-803 [Abstract] [Full Text]  
  • McAllister, A., Arbetman, A. E., Mandl, S., Peña-Rossi, C., Andino, R. (2000). Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases. J. Virol. 74: 9197-9205 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»